Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma

Molecular Cancer Research

Volumn 5, Issue 2, 2007, Pages 145-151

  Mohapatra, Subhra ^a   Coppola, Domenico ^a   Riker, Adam I ^b   Pledger, W Jack ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b University of South Alabama Mitchell Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P53; ROSCOVITINE; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MELANOMA; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PROTEIN KINASE INHIBITORS; PURINES; SKIN NEOPLASMS; TISSUE CULTURE TECHNIQUES;

EID: 33947249150     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0300     Document Type: Article

References (34)

1. Campioni M, Santini D, Tonini G, et al. Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp Dermatol 2005; 14: 811-8.
2. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003;199:275-88.
3. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-51.
4. Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 2006;19:19-25.
5. Tsao H, Sober AJ. Melanoma treatment update. Dermatol Clin 2005;23: 323-33.
6. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006;20:2149-82.
7. Senderowicz AM. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther 2003;2:S84-95.
8. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22:6609-20.
9. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5. Eur J Biochem 1997;243:527-36.
10. Dai Y, Dent P, Grant S. Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A. Cell Cycle 2002;1:143-52.
11. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8.
12. Mohapatra S, Chu B, Wei S, et al. Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res 2003;63:8523-30.
13. Hahntow IN, Schneller F, Oelsner M, et al. Cyclin-dependent kinase inhibitor roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004;18:747-55.
14. Mohapatra S, Chu B, Zhao X, Pledger WJ. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 2005;65:7717-23.
15. MacCallum DE, Melville J, Frame S, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005;65:5399-407.
16. Fischer PM, Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 2005;14:457-77.
17. Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, Workman P. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Mol Cancer Ther 2004;3:353-62.
18. Raynaud FI, Whittaker SR, Fischer PM, et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted amino-purine cyclin-dependent kinase inhibitors olomoucine, bohemine, and CYC202. Clin Cancer Res 2005;11:4875-87.
19. Nutley BP, Raynaud FI, Wilson SC, et al. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther 2005;4:125-39.
20. Berking C, Herlyn M. Human skin reconstruct models: a new application for studies of melanocyte and melanoma biology. Histol Histopathol 2001;16: 669-74.
21. Meier F, Nesbit M, Hsu MY, et al. Human melanoma progression in skin reconstructs: biological significance of bFGF. Am J Pathol 2000;156:193-200.
22. Meier F, Caroli U, Satyamoorthy K, et al. Fibroblast growth factor-2 but not Mel-CAM and/or β3 integrin promotes progression of melanocytes to melanoma. Exp Dermatol 2003;12:296-306.
23. Hsu MY, Meier FE, Nesbit M, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 2000;156:1515-25.
24. Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004;6:565-76.
25. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.
26. Akslen LA, Monstad SE, Larsen B, Straume O, Ogreid D. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int J Cancer 1998;79:91-5.
27. Kumar R, Smeds J, Berggren P, et al. A single nucleotide polymorphism in the 3′untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4, and p53 genes are rare. Int J Cancer 2001;95:388-93.
28. Bell E, Ehrlich HP, Buttle DJ, Nakatsuji T. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science 1981;211:1052-4.
29. Holbrook KA, Hennings H. Phenotypic expression of epidermal cells in vitro: a review. J Invest Dermatol 1983;81:11-24s.
30. Bach S, Knockaert M, Reinhardt J, et al. Roscovitine targets, protein kinases, and pyridoxal kinase. J Biol Chem 2005;280:31208-19.
31. Riker AI, Jove R, Daud AI. Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front Biosci 2006;11:1-14.
32. O'Day S, Boasberg P. Management of metastatic melanoma 2005. Surg Oncol Clin N Am 2006;15:419-37.
33. Riker AI. Isolation and culture of melanoma cell lines. Methods Mol Med 2004;88:93-9.
34. Mohapatra S, Agrawal D, Pledger WJ. p27Kip1 regulates T cell proliferation. J Biol Chem 2001;276:21976-83.